Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Company Overview

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes. The company’s research platform leverages a proprietary chemokine-targeted approach to address underlying disease mechanisms rather than solely treating symptoms. By focusing on the molecular cues that recruit pro-fibrotic cells, Sagimet aims to develop therapies with the potential for disease modification in conditions that today have limited treatment options.

Headquartered in the San Francisco Bay Area, Sagimet Biosciences operates research and development facilities that support both in-house discovery and collaborative initiatives with academic and industry partners. Since its formation in 2020, the company has built a team of scientists and clinicians with expertise in fibrosis biology, protein engineering and translational medicine. This multidisciplinary organization is structured to accelerate candidates from early discovery through proof-of-concept studies.

Sagimet’s leadership team is led by President and Chief Executive Officer Dr. Steven Landis, a recognized expert in fibrotic disease research and a co-founder of the company’s predecessor, Cirius Therapeutics. Under Dr. Landis’s guidance, Sagimet has established a clear clinical development plan for CM-101 and is advancing strategic collaborations to expand its pipeline. The company’s strategic vision is centered on delivering first-in-class and best-in-class therapies for patients with high-unmet-need fibrotic disorders.

Key Stats

• Today's Range: $6.86 to $7.20
• 50-Day Range: $6.30 to $7.99
• 52-Week Range: $4.50 to $11.41
• Volume: 910,905 shs
• Average Volume: 1.35 million shs
• Market Capitalization: $230.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.57
• Consensus Rating: Moderate Buy

Sagimet Biosciences Stock Analysis - MarketRank™

Sagimet Biosciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 463rd out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sagimet Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Sagimet Biosciences has a consensus price target of $25.57, representing about 261.7% upside from its current price of $7.07.

Amount of Analyst Coverage

Sagimet Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sagimet Biosciences are expected to grow in the coming year, from ($1.15) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sagimet Biosciences is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sagimet Biosciences is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sagimet Biosciences has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

33.79% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Sagimet Biosciences has recently increased by 18.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sagimet Biosciences does not currently pay a dividend.

Dividend Growth

Sagimet Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.87

News Sentiment

Sagimet Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sagimet Biosciences this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sagimet Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.50% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/24/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SGMT
• CIK: 1400118
• Web: sagimet.com
• Phone: 650-561-8600
• Fax: N/A
• Employees: 8
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Sagimet Biosciences: $25.57
• High Price Target: $49.00
• Low Price Target: $8.00
• Potential Upside/Downside: +261.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.57%
• Return on Assets: -35.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.33
• Quick Ratio: 20.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.42 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 32,585,000
• Free Float: 28,838,000
• Market Cap: $230.38 million
• Optionable: Optionable
• Beta: 3.35